Summary & Overview

CPT 0363U: Cxbladder Triage Urine Gene Expression Test

CPT code 0363U designates a Proprietary Laboratory Analyses (PLA) test for Cxbladder™ Triage, a urine-based molecular diagnostic that evaluates expression of five genes and uses an algorithm plus clinical data to estimate the probability of urothelial (bladder) cancer. As a PLA code, 0363U is specific to Pacific Edge Diagnostics USA Ltd.'s test and identifies a unique proprietary assay rather than a class of similar tests. Nationally, this code matters because it affects coding, coverage reviews, and claims processing for a noninvasive adjunct to bladder cancer evaluation.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical purpose of the test, the service setting and specimen type, common modifiers associated with laboratory billing, and which major payers are considered. The publication summarizes typical coverage considerations for proprietary molecular diagnostics, highlights billing and clinical context for use as a triage test in patients with suspected urothelial cancer, and outlines where to find payer-specific policy details.

This summary is intended for a national audience of payers, providers, and billing professionals seeking concise guidance on what CPT code 0363U represents, how it is used clinically, and which major payers are included in the coverage discussion. Data not available in the input will be noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0363UCPTProprietary Laboratory Analysesmolecular diagnosticsurine testingurothelial cancerCxbladderlaboratory billingdiagnostic algorithm

Billing Code Overview

CPT code 0363U is a Proprietary Laboratory Analyses (PLA) code that applies only to a single, specific laboratory test: Cxbladder™ Triage from Pacific Edge Diagnostics USA Ltd. The test analyzes gene expression of five genes in a urine specimen and applies an algorithmic analysis, combined with patient clinical data, to report the probability that a patient has urothelial (bladder) cancer.

Service Type: Molecular diagnostic urine test (proprietary gene expression assay)

Typical Site of Service: Clinical laboratory or independent diagnostic testing facility (urine specimen collection may occur in outpatient clinics or physician offices and the specimen is sent to the performing laboratory)

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult presenting to urology or primary care with hematuria, persistent urinary symptoms, or a history of prior urothelial (bladder) cancer under surveillance. The clinician collects a voided urine specimen during an office visit or sends a refrigerated/stabilized sample from an outpatient collection site to the laboratory performing the proprietary Cxbladder™ Triage test (0363U). Clinical workflow: the provider documents patient history, physical exam, and indications (for example gross or microscopic hematuria, new irritative voiding symptoms, or surveillance after transurethral resection). The specimen is labeled and shipped with required patient clinical data. The laboratory performs gene expression analysis of the five specified genes and runs the proprietary algorithm combining molecular results with clinical variables to report a probability score for urothelial carcinoma. Results are returned to the ordering clinician who integrates the report with imaging, cystoscopy, or urine cytology to guide further diagnostic evaluation or surveillance planning.

Coding Specifications

Modifier	Description	When to Use
`00`	Default/No modifier	Use when no other modifier applies to the service billed.
`26`	Professional component	Use when billing only the physician professional component if the laboratory separates professional and technical components (rare for PLA tests).
`52`	Reduced service	Use when the laboratory test was performed but was partially reduced in scope or time.
`53`	Discontinued procedure	Use if the specimen/test could not be completed and the service was discontinued for clinical reasons.
`54`	Surgical care only	Generally not applicable to PLA but included when only part of a multi-component service is performed by one provider.
`55`	Postoperative care only	Rarely applicable; use only if relevant in a split-care scenario.
`62`	Two surgeons	Uncommon for a lab PLA; included for completeness when two providers share responsibility.
`78`	Unplanned return to OR by same physician following initial procedure	Not typical for this test; use only if clinically applicable in combined care episodes.
`80`	Assistant surgeon	Not typical for lab testing; use only if an assistant surgeon is separately billing related surgical procedures.
`QK`	Medical direction of two, three, or four assistants	Use only in situations involving billed assistant services; not routinely used for `0363U`.
`QX`	CRNA service with medical direction	Not applicable to PLA testing; include when relevant to associated anesthesia services.
`QY`	Medical direction of one CRNA by an anesthesiologist	As above, not routine for the lab test.
`TC`	Technical component	Use when billing only the laboratory technical component if the PLA allows split billing of technical vs professional components.
`SH`	Diagnostic service ordered by another physician	Use when another physician ordered the test and billing needs to reflect that ordering relationship.

Taxonomy Code	Specialty	Notes
`207L00000X`	Urology	Urologists commonly order Cxbladder™ for hematuria evaluation and surveillance of bladder cancer.
`207Q00000X`	Obstetrics & Gynecology	Gynecologists may order urine-based tests for hematuria evaluation in female patients.
`208D00000X`	Family Medicine	Primary care physicians frequently initiate hematuria workup and order urine-based diagnostics.
`208U00000X`	Internal Medicine	Internists similarly order noninvasive urine testing during evaluation of urinary symptoms.
`335E00000X`	Pathology & Clinical Laboratory	Clinical pathologists and laboratory directors oversee testing protocols and result interpretation in the lab.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`R31.0`	Gross hematuria	Visible blood in urine is a primary indication to evaluate for urothelial carcinoma using `0363U`.
`R31.1`	Microscopic hematuria	Asymptomatic microscopic hematuria prompts noninvasive testing including urine molecular assays.
`N32.0`	Bladder neck obstruction	Lower urinary tract pathology causing hematuria or irritative symptoms that may prompt evaluation with urine testing.
`N13.30`	Unspecified obstructive uropathy, unspecified kidney	Obstructive uropathy may be part of the differential when evaluating urinary symptoms with molecular urine testing.
`Z85.51`	Personal history of malignant neoplasm of bladder	Patients with prior bladder cancer are monitored with urine-based tests such as Cxbladder™ for recurrence surveillance.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`81000`	Urinalysis, without microscopy	Pre-analytical screening test often performed prior to ordering molecular urine assays such as `0363U`.
`81001`	Urinalysis, by dip stick or tablet reagent; automated, without microscopy	Rapid clinic-screen test performed at point of care before sending specimen for PLA testing.
`88112`	Cytopathology, fluids, washings or brushings, except gynecologic, for interpretation; requiring interpretation by physician	Urine cytology commonly performed alongside molecular assays for bladder cancer detection and surveillance.
`51798`	Measurement of post-void residual urine; non-imaging	Urologic evaluation adjunct sometimes performed during hematuria workup in the same clinical episode.
`52000`	Cystourethroscopy (separate procedure)	Diagnostic cystoscopy is commonly performed before or after urine-based molecular testing when clinical suspicion remains or to localize lesions.